Parexel Launches Genomic Medicine Team
The team joined Parexel from GlaxoSmithKline’s Genetics and Computational Biology departments and expands capabilities in genomic-based drug development.
Parexel has expanded services and capabilities in genomic-based drug development with its Genomic Medicine team. The team is comprised of more than 15 scientists with combined expertise in genomics, drug discovery, and drug development, who joined Parexel from GlaxoSmithKline’s Genetics and Computational Biology departments. The team will meet clients’ expected increased needs for the number of personalized medicines that will require genomic information to inform decision-making on the clinical utility and value for the intended patient population.
Read the full release.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
